Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the 14th annual BIO CEO & Investor Conference at 8:30 a.m. EST / 5:30 a.m. PST on Tuesday, February 14, 2012, in New York. During the presentation, Dr. Morrissey will discuss the company's development program and plans for cabozantinib, and review the most recent publicly available data for the compound. He will also provide a general business update, including the company's financial outlook for 2012.
The presentation will be webcast and may be accessed in the Event Calendar page under Investors at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com
Contacts:
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor
Relations and Corporate Communications
cbutler@exelixis.com
